Japanese Minister Says PMDA Not Excluded From Streamlining Review
This article was originally published in PharmAsia News
Minister of Administrative Reform Sachio Edano said the nation's pharmaceutical review body - the Pharmaceutical and Medical Device Agency - will be subject to a streamlining review. Edano didn't pinpoint problems within the PMDA, yet said that all administrative agencies are subject to such a review. The minister made the statement during an interview with online journalists. (Click here for more - Japanese language
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.